National Advisory Committee on Immunization (NACI): Statements and publications

Canadian Immunization Guide (CIG) chapter

• Bacille Calmette-Guérin (BCG) Vaccine

New statements

• None

Previous statements

• 2005 – Statement on Bacille Calmette-Guérin (BCG) Vaccine - Erratum
• 2004 – Statement on Bacille Calmette-Guérin (BCG) Vaccine

Canadian Immunization Guide (CIG) chapter

• Diphtheria Toxoid

New statements

• 2018 – Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
  • Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
  • CCDR – Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine

Previous statements

• 2014 – Statement on the booster for 4-6 year-olds for protection against pertussis
• 2014 – Update on pertussis vaccination in pregnancy
• 2007 – Statement on the recommended use of pentavalent and hexavalent vaccines
  • Literature review on DTaP based penta- and hexavalent vaccines approved for clinical use in Canada (2006)
• 2005 – Interval between administration of vaccines against diphtheria, tetanus, and pertussis
• 2005 – Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age
• 2003 – Prevention of pertussis in adolescents and adults
  • Clarification - Prevention of pertussis in adolescents and adults (2004)
• 2000 – Statement on adult/adolescent formulation of combined acellular pertussis, tetanus and diphtheria vaccine

Canadian Immunization Guide (CIG) chapter

• Haemophilus influenzae Type B Vaccine

New statements

• None

Previous statements

• 2007 – Statement on the recommended use of pentavalent and hexavalent vaccines
• 2005 – Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilius influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age

Canadian Immunization Guide (CIG) chapters

• Hepatitis A Vaccine
• Hepatitis B Vaccine

New statements

• 2017 – Update on the recommended use of hepatitis B vaccine
  • CCDR – Summary of the NACI update on the recommended use of hepatitis B vaccine
• 2016 – Update on the recommended use of hepatitis A vaccine
  • CCDR - Summary of the NACI statement update on the recommended use of hepatitis A vaccine

Previous statements

• 2007 – Statement on the recommended use of pentavalent and hexavalent vaccine
• 2001 – Update on Hepatitis A vaccine (AVAXIM®, Aventis Pasteur)
• 2000 – Supplementary statement on hepatitis A vaccine
• 2000 – Statement on alternate adolescent schedule for hepatitis B
• 1999 – Supplementary statement on hepatitis prevention – hepatitis A and hepatitis B combination vaccine for children
• 1999 – Statement on combination vaccines against hepatitis A and hepatitis B

Canadian Immunization Guide (CIG) chapter

• Herpes Zoster (Shingles) Vaccine

New statements

• 2018 – Updated recommendations on the use of herpes zoster vaccines
  • Literature review on the immunogenicity of herpes zoster vaccines
  • CCDR – Summary of the NACI update on herpes zoster vaccines

Previous statements

• 2014 – Update on the use of herpes zoster vaccine
• 2010 – Statement on the recommended use of herpes zoster vaccine

Canadian Immunization Guide (CIG) chapter

• Human Papillomavirus (HPV) Vaccine

New statements

• 2017 – Updated recommendations on human papillomavirus (HPV) vaccine: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations
  • NACI literature review for HPV immunization of immunocompromised populations
  • CCDR – Summary of the NACI update on the recommended use of HPV vaccine: Nine-valent HPV vaccine two-dose immunization schedule and the use of HPV vaccine in immunocompromised populations
• 2016 – Updated recommendations on human papillomavirus vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule
  • CCDR – Summary of NACI’s updated recommendations on HPV vaccines: Nine-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule
• 2015 – Update on the recommended human papillomavirus (HPV) vaccine immunization schedule
  • Amendment to the 2015 “Update on the recommended human papillomavirus vaccine schedule”
  • CCDR – Summary of the National Advisory Committee on Immunization’s update on the recommended human papillomavirus (HPV) vaccine immunization schedule

Previous statements

• 2012 – Update on human papillomavirus vaccines
• 2007 – Statement on human papillomavirus vaccine
  • Literature review on HPV 6, 11, 16 and 18: Disease and vaccine characteristics (2007)

Current statement

• Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020–2021

New statements

• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2019-2020
  • Literature review on the comparative effectiveness and immunogenicity of subunit and split virus inactivated influenza vaccines in adults 65 years of age and older (2018)
  • CCDR – Summary of the NACI literature review on the comparative effectiveness of subunit and split virus inactivated influenza vaccines in older adults (2018)
  • CCDR – Summary of the NACI seasonal influenza vaccine statement for 2019-2020
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2018-2019
  • Literature review on individuals with neurologic or neurodevelopment conditions and risk of serious influenza-related complications (2018)
  • Literature review update on the efficacy and effectiveness of high-dose (Fluzone® High-Dose) and MF-59-adjuvanted (Fluad®) trivalent inactivated influenza vaccines in adults 65 years of age and older (2018)
  • Supplemental statement – Afluria Tetra® - An advisory committee statement (ACS) (2018)
  • CCDR – Summary of the NACI seasonal influenza vaccine statement for 2018-2019
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2017-18
  • Addendum - Influvac® use in children (2017)
  • CCDR – Summary of the NACI seasonal influenza vaccine statement for 2017-2018
  • CCDR – Addendum to the NACI statement on seasonal influenza vaccine for 2017-18
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2016-17
  • Addendum – LAIV use in egg allergic individuals (2016)
  • Addendum – LAIV use in children and adolescents (2016)
  • CCDR – Summary of the NACI seasonal influenza vaccine statement for 2016-2017
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2015-16
  • Literature review on Pediatric Fluad® influenza vaccine use in children 6-72 months of age (2015)
  • CCDR – Summary of the NACI seasonal influenza vaccine statement for 2015-2016

Previous statements

• 2016 – Literature review of high dose seasonal influenza vaccine for adults 65 years and older
• 2015 – Opinion on live attenuated influenza vaccine (LAIV) effectiveness in young children
• 2014 – Influenza vaccine effectiveness, immunogenicity, and safety in health adults 19-64 years old
• 2014 – Literature review on influenza vaccination in healthy 5-18 year olds
• 2014 – Literature review on quadrivalent influenza vaccines
• 2014 – Statement on seasonal influenza vaccine for 2014-15
• 2013 – Statement on seasonal influenza vaccine for 2013-14
  • Revised wording to the National Advisory Committee on Immunization (NACI) recommendation for live attenuated influenza vaccine (LAIV) in healthy children and adolescents 2-17 years of age
• 2012 – Statement on seasonal influenza vaccine for 2012-13
• 2011 – Statement on seasonal influenza vaccine for 2011-12
  • Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental statement on seasonal influenza vaccine for 2011-12
  • Recommendations on the use of MF59-adjuvanted trivalent influenza vaccine (Fluad®): Supplemental statement on seasonal influenza vaccine for 2011-12
• 2010 – Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2010-2011
  • Addendum to the 2010-2011 seasonal trivalent inactivated influenza vaccine (2011)
• 2009 – Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2009-2010
• 2008 – Statement on influenza vaccination for the 2008-2009 season
• 2007 – Statement on influenza vaccination for the 2007-2008 season
• 2006 – Statement on influenza vaccination for the 2006-2007 season
• 2005 – Statement on influenza vaccination for the 2005-2006 season
  • Update on influenza vaccination for the 2005-2006 season (2006)
• 2004 – Statement on influenza vaccination for the 2004-2005 season
• 2003 – Statement on influenza vaccination for the 2003-2004 season
• 2002 – Statement on influenza vaccination for the 2002-2003 season
  • Supplementary statement for the 2002-2003 influenza season: Update on oculo-respiratory syndrome in association with influenza vaccination
• 2001 – Statement on influenza vaccination for the 2001-2002 season
  • Supplementary statement for the 2001-2002 season: Influenza vaccination of persons who experienced oculo-respiratory syndrome following previous influenza vaccination
• 2000 – Statement on influenza vaccination for the 2000-2001 season
  • Supplementary statement on influenza vaccination: Continued use of Fluviral® influenza vaccine in the 2000-2001 season (2001)

Canadian Immunization Guide (CIG) chapter

• Measles Vaccine

New statements

• 2018 – CCDR - Updated NACI recommendations for measles post-exposure prophylaxis
• 2016 – Update on measles-mumps-rubella-varicella vaccine and febrile seizures

Previous statements

• 2010 – Statement on measles-mumps-rubella-varicella vaccine
• 2010 – Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals
• 1998 - Measles Surveillance: Guidelines for Laboratory Support
• 1996 - Interim advisory on measles revaccination of persons with Acquired Immunodeficiency Syndrome (AIDS)
• 1996 - Supplementary statement on measles elimination in Canada
• 1996 - Supplementary statement on MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens
• 1995 - Guidelines for control of measles outbreaks in Canada

Canadian Immunization Guide (CIG) chapter

• Meningococcal Vaccine

New statements

• 2020 - The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease
• 2015 – Update on quadrivalent meningococcal vaccines available in Canada
  • CCDR – Summary of the National Advisory Committee on Immunization’s update on quadrivalent meningococcal vaccines available in Canada

Previous statements

• 2014 – Advice for the use of the multicomponent meningococcal serogroup B (4CMenB) vaccine
  • Literature review on serogroup B invasive meningococcal disease: epidemiology, multicomponent meningococcal B vaccine characteristics and other factors for consideration
• 2013 – Update on the use of quadrivalent conjugate meningococcal vaccines
• 2009 – Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations
• 2007 – Meningococcal C conjugate for infants statement
• 2007 – Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135
• 2005 – Update on meningococcal C conjugate vaccines
• 2003 – Supplementary statement on conjugate meningococcal vaccines
• 2001 – Statement on the recommended use of meningococcal vaccines

Canadian Immunization Guide (CIG) chapter

• Mumps Vaccine

New statements

• 2016 – Update on measles-mumps-rubella-varicella vaccine and febrile seizures

Previous statements

• 2010 – Statement on measles-mumps-rubella-varicella vaccine
• 2010 – Guidelines for the prevention and control of mumps outbreaks in Canada
• 2010 – Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals
• 2007 – Statement on mumps vaccine
• 1996 – Supplementary statement on MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens

Canadian Immunization Guide (CIG) chapter

• Pertussis Vaccine

New statements

• 2018 – Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
  • Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
  • CCDR – Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine

Previous statements

• 2014 – Statement on the booster for 4-6 year-olds for protection against pertussis
• 2014 – Update on pertussis vaccination in pregnancy
• 2007 – Statement on the recommended use of pentavalent and hexavalent vaccines
  • Literature review on DTaP based penta- and hexavalent vaccines approved for clinical use in Canada (2006)
• 2005 – Interval between administration of vaccines against diphtheria, tetanus, and pertussis
• 2005 – Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age
• 2003 – Prevention of pertussis in adolescents and adults
  • Clarification - Prevention of pertussis in adolescents and adults (2004)
• 2000 – Statement on adult/adolescent formulation of combined acellular pertussis, tetanus and diphtheria vaccine

Canadian Immunization Guide (CIG) chapter

• Pneumococcal Vaccine

New statements

• 2018 – Update on the use of pneumococcal vaccines in adults 65 years of age and older – A public health perspective
• 2016 – Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim recommendation
  • CCDR – Summary of NACI statement: Interim recommendations on the use of pneumococcal vaccines in immunocompetent adults 65 years of age and older
• 2015 – Re-immunization with polysaccharide 23-valent pneumococcal vaccine (PNEU-P-23)
  • CCDR – Summary of the National Advisory Committee on Immunization’s statement on the re-immunization with polysaccharide 23-valent pneumococcal vaccine

Previous statements

• 2014 – Update on the use of pneumococcal vaccines: Addition of asthma as a high-risk condition
• 2013 – Statement on the use of conjugate pneumococcal vaccine – 13 valent in adults (PNEU-C-13)
• 2010 – Update on the use of conjugate pneumococcal vaccines in childhood
• 2010 – Update on pediatric invasive pneumococcal disease and recommended use of conjugate pneumococcal vaccines
• 2008 – Statement on the recommended use of pneumococcal 23-valent polysaccharide vaccine in homeless persons and injection drug users
• 2006 – Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants
• 2004 – Recommendations for use of pneumococcal 23-valent polysaccharide vaccine during shortage
• 2002 – Statement on the recommended use of pneumococcal conjugate vaccine
  • Addendum (2003)

Canadian Immunization Guide (CIG) chapter

• Poliomyelitis Vaccine

New statements

• None

Previous statements

• 2007 – Statement on the recommended use of pentavalent and hexavalent vaccines
• 2005 – Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age

Canadian Immunization Guide (CIG) chapter

• Rabies Vaccine

New statements

• None

Previous statements

• 2009 – Recommendations regarding the management of bat exposures to prevent human rabies
• 2005 – Update on rabies vaccines

Canadian Immunization Guide (CIG) chapter

• Rotavirus Vaccine

New statements

• 2016 – Statement on rotavirus vaccines and intussusception

Previous statements

• 2010 – Updated statement on the use of rotavirus vaccines
  • Literature review on rotavirus: Disease and vaccine characteristics
• 2008 – Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine

Canadian Immunization Guide (CIG) chapter

• Rubella Vaccine

New statements

• 2016 – Update on measles-mumps-rubella-varicella vaccine and febrile seizures

Previous statements

• 2010 – Statement on measles-mumps-rubella-varicella vaccine
• 2010 – Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals
• 1996 - Supplementary statement on MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens

Canadian Immunization Guide (CIG) chapter

• Smallpox Vaccine

New statements

• None

Previous statements

• 2002 – Statement on smallpox vaccination

Canadian Immunization Guide (CIG) chapter

• Tetanus Toxoid

New statements

• 2018 – Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
  • Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
  • CCDR – Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine

Previous statements

• 2014 – Statement on the booster for 4-6 year-olds for protection against pertussis
• 2014 – Update on pertussis vaccination in pregnancy
• 2007 – Statement on the recommended use of pentavalent and hexavalent vaccines
  • Literature review on DTaP based penta- and hexavalent vaccines approved for clinical use in Canada (2006)
• 2005 – Interval between administration of vaccines against diphtheria, tetanus, and pertussis
• 2005 – Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type B combination vaccines presently approved for use in Canada for children less than 7 years of age
• 2003 – Prevention of pertussis in adolescents and adults
  • Clarification - Prevention of pertussis in adolescents and adults (2004)
• 2000 – Statement on adult/adolescent formulation of combined acellular pertussis, tetanus and diphtheria vaccine

Canadian Immunization Guide (CIG) chapter

• Varicella (Chickenpox) Vaccine

New statements

• 2016 – Updated recommendations for the use of varicella zoster immune globulin (VarIg) for the prevention of varicella in at-risk patients
• 2015 – Varicella proof of immunity – 2015 update

Previous statements

• 2010 – Varicella vaccination two-dose recommendations
  • Literature review on one-dose and two-dose varicella vaccination
• 2010 – Statement on measles-mumps-rubella-varicella vaccine
• 2010 – Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals
• 2006 – Varizig™ as the varicella zoster immune globulin for the prevention of varicella in at-risk patients
• 2004 – Update on varicella
• 2002 – NACI update to statement on varicella vaccine
• 1999 – Statement on recommended use of varicella virus vaccine

New statements

• 2020 - Interim guidance on continuity of immunization programs during the COVID-19 pandemic

Previous statements

• 2007 – Thimerosal: Updated statement
• 2005 – Updated recommendations on the use of thimerosal-containing vaccines in Canada
• 2003 – Statement on thimerosal
• 2003 – Immunization for cochlear implant recipients
• 2003 – Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab)
• 2000 – Statement on immunization for Lyme disease
• 1999 – Thimerosal in vaccines